In most cases, the upregulation of SETD5 is detected in pancreatic cancer, breast cancer, esophageal squamous cell carcinoma (ESCC), and non-small cell lung cancer (NSCLC) (13, 23, 56, 57). This evidence concerns the gene SETD5 and breast carcinoma.